PARPis have demonstrated substantial efficacy in BRCA1/2 breast and ovarian cancers until the point of tumor resistance, after which point progression of disease ensues, and the once effective therapy is essentially useless in affected patients. Here, BRCA1 is linked to ovarian carcinoma.